John Oluwafemi Teibo: New Insights into CAR-T Molecular Effectors and Signaling Pathways
John Oluwafemi Teibo, Membership Associate at Royal Society of Chemistry, shared a post on LinkedIn:
”Excited to share that our work has been published read here.
CAR-T cell is an innovative therapy, but there is no clear understanding of the molecular mechanisms and signalling pathways utilized by CAR-T cells hence we studied the early event molecular effectors of the CAR-T cell therapy in which these proteins, CD74, CD247, CD28, DAP, LCK, p38 MAPK, and CASP3, play roles, and inhibition of one of them, LCK, using Dasatinib, can regulate CAR-T cell responses.
This finding can promote the efficient design of this innovative cancer treatment strategy in which protein candidates may also lead to the identification of adjuvant regulation of CAR-T responses. This is a follow-up work on our initial review on the molecular effectors globally for CAR-T cell, irrespective of construct and design – read here.
This is a collaborative work that cut across various labs in Brazil, Germany, and the UK, where I was a visiting PhD student. I’m grateful for the guidance from my supervisors Vitor Faça, Lucas E. Botelho de Souza, Virginia Picanço and visiting supervisors Raja Sekhar Nirujogi and Dario Alessi.
Special thanks to all the authors for their contributions, as well as to the funding bodies – FAPESP, Royal Society of Chemistry, CNPq, CAPES (Coordination for the Improvement of Higher Education Personnel), International Union of Biochemistry and Molecular Biology (IUBMB), European Association for Cancer Research (EACR), Biochemical Society – and to the institutions CTC USP, Hemocentro de Ribeirão Preto, and the Ribeirão Preto Medical School (FMRP) at USP.
God Almighty be praised and Jesus be glorified.”
Title: Proteomics analysis reveal early event molecular effectors of anti-CD19 CAR-T cell therapy in hematological cancer☆
Authors: John Oluwafemi Teibo, Roberta Maraninchi Silveira, Virginia Campos Silvestrini, Izadora Archiolli, Ana Paula Masson, Beatriz Pereira de Morais, Dayane Schmidt, Matheus Henrique dos Santos, Germano Aguiar Ferreira, Carolina Hassibe Thomé, Dominic Helm, Raja Sekhar Nirujogi, Dario Renato Alessi, Virginia Picanço-Castro, Lucas Eduardo Botelho de Souza, Vitor Marcel Faça
More posts featuring John Oluwafemi Teibo.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023